Strides Pharma passes US FDA inspection at Singapore facility

Published: 10-Aug-2022
Regulatory Finance Pharmaceutical

The global pharma company has completed the inspection with zero 483 observations

Strides Pharma Science has announced that its formulation facility in Singapore underwent a US FDA inspection that ended in early August 2022.

The inspection was completed successfully with Zero 483 observations.

The US is one of the key focus markets for Strides and the company has given a growth outlook of US$250m in FY23 for the US business. The company has set a target to launch ~ 20 new products every year in the US. The company has 279 cumulative ANDA filings (including recently acquired portfolio from Endo at Chestnut Ridge) with USFDA of which 259 ANDAs have been approved and 20 are pending approval.

The company has a diversified manufacturing base with 5 USFDA-approved facilities which are capable of catering to multiple dosage formats including niche capabilities in controlled Substances, Hormones, Nasal Sprays, Gels, Modified Release products, Liquids.

  • Companies:
  • US Food and Drug Administration (FDA)
See more

You may also like

Regulatory

Interview with FDA Press Officer Charles Kohler from CDER

Read more
The FDA Press Officer from CDER talks about how to navigate the compliance pathways for those in the pharmaceutical industry. Written by Tom McGhie from Cleanroom Technology

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    What is ISO 8 cleanroom classification? Each cleanroom class is denoted by a maximum concentration of particles per cubic meter or cubic foot of air. ISO 8 is the second lowest cleanroom classification
  2. The three musketeers of pharmaceutical quality control GMP, GAMP5, and 21CFR11 explained
  3. APIs: Bioreactor hoists with a multipurpose twist Peter Devenny of PalPharma describes the solution for a biotech facility in Switzerland designed to handle filled bioreactors across GMP areas to produce ten metric tons of antibody per year
  4. A guide to cleanroom wall systems Discover the best wall panel options for your cleanroom’s performance and compliance needs

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Interview with FDA Press Officer Charles Kohler from CDER

The FDA Press Officer from CDER talks about how to navigate the compliance pathways for those in the pharmaceutical industry. Written by Tom McGhie from Cleanroom Technology
Regulatory

FDA Warning Letter: ImprimisRx facility features stained HEPA filters

Following a 2022 inspection, ophthalmic medicine production expert ImprimisRx received a 483 form. A year later a warning letter has been sent emphasising major issues with the facility design and operation
Regulatory

Warning Letters: Lessons from an FDA Captain

Redica Systems’ Jerry Chapman talks to FDA's Ileana Barreto-Pettit
Regulatory

Abraxis Bioscience receives FDA warning

During the examination, FDA officials found that the company “failed to thoroughly investigate any unexplained discrepancy or failure of a batch”
Regulatory

FDA gives out 483 form to Torrent Pharma citing "inadaquate cleaning procedure"

The pharma giant from India has been give the form citing three main issues
Cleaning

Study finds $1 per reaction LAMP assay works for BCC testing

The novel assay has been assessed for detecting the bacteria responsible for many pharmaceutical product recalls, Burkholderia cepacia complex
Cleaning

Understanding cleanroom behaviours in compounding pharmacies

Protecting patients from poor-quality compounded drugs is a fundamental part of the US Food and Drug Administration’s (FDA) drug compounding programme and the pharmacies must adhere to strict cleanliness standards. FDA Microbiologist, Djamila Harouaka, explains
Subscribe now